Ascelia Pharma (ACE) investor relations material

Executive summary

• Q3 priorities: evaluate U.S. and European regulatory paths for Orviglance, continue partnering efforts, and prepare Oncoral development and outreach.

• FDA minutes identified clinical utility as the key remaining question; prospective reanalysis of existing SPARKLE images using a new primary endpoint may address the evidence requirement.

Financial highlights

• Q3 operating loss was SEK 10.4m versus SEK 15.3m; net loss was SEK 10.3m versus SEK 15.7m, primarily reflecting lower R&D and personnel costs.

• Q3 R&D costs were SEK 7.8m and SG&A costs SEK 2.6m, down from SEK 8.8m and SEK 3.3m in Q2.

• 9M operating loss was SEK 39.0m versus SEK 58.6m; net loss was SEK 38.7m versus SEK 60.4m.

• Liquid assets were SEK 27.8m at 30 September 2026, versus SEK 72.3m a year earlier and SEK 49.9m at year-end 2025.

Outlook and guidance

• Cash runway is expected to extend into Q2 2027; priorities include FDA feedback on a proposed SPARKLE reanalysis and European regulatory feedback on the current data package.

• U.S. regulatory planning using existing SPARKLE data depends on FDA acceptance; further clinical studies may be required.

• Orviglance partnering efforts continue; Oncoral is positioned to advance toward Phase 2, with development and partnering preparations ongoing.